Henrik Schimmell – President, Radiometer
Henrik Schimmell outlines the critical importance of blood gas testing – a field in which Radiometer has long been a pioneer – and how the company’s portfolio of diagnostic tools…
Company Description
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Denmark A/S
Orestads Boulevard 67
2300 Copenhagen S
Denmark
Phone: +45 7741 5757
Fax: +45 7741 5799
Biogen Idec (Denmark) Manufacturing Aps
Biogen Idec Allé 1
3400 Hillerød
Denmark
Phone: +45 7741 6000
Fax: +45 7741 6070
www.biogenidec.dk
Henrik Schimmell outlines the critical importance of blood gas testing – a field in which Radiometer has long been a pioneer – and how the company’s portfolio of diagnostic tools…
In a wide-ranging and candid conversation, Siemens Healthineers’ Tisha Boatman discusses uprooting from the US to Denmark, how Danish hospital tendering needs to evolve beyond price considerations alone, the challenges…
Kenneth Mikkelsen & Jeroen ter Borg describe the work of IQVIA – the world’s biggest CRO and life science data services provider – in Denmark, which has served as a…
Servier’s Estève Speranza outlines the rationale behind the French group’s reorganisation in the Nordic countries, how the global shift towards oncology is playing out in his region, and the Nordics’…
Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including…
The BioInnovation Institute (BII) is an initiative from the Novo Nordisk Foundation which aims to support entrepreneurial researchers and early-stage life science start-ups with up to DKK 18 million in…
Lisbeth Nielsen of the Danish Health Data Authority outlines the organisation’s purpose and mission, how it contributed to Denmark’s robust COVID-19 response, and the challenges of making Denmark’s comprehensive patient…
Alphalyse is a Danish contract research organization (CRO) specialising in protein chemistry, mass spectrometry, and bioinformatics. The firm’s co-founder & COO Ejvind Mørtz outlines its journey since its foundation in…
Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through…
Newly appointed Director of Invest in Denmark Anne Hougaard Jensen outlines her initial priority list, how the agency is dialling in on the areas in which Denmark has a particular…
Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the…
Dr Tina Hahn explains how AXON positions itself as a strategic partner for its Danish clients in their scientific communication work, highlights how the COVID-19 pandemic has foregrounded the importance…
See our Cookie Privacy Policy Here
